Table 7 |
||||||
|
Sensitivity analyses of NashTest for the diagnosis of Borderline Nash or Nash versus No Nash [Area under the ROC curves (AUROCs)], according to group, ALT values, alcohol consumption, quality of biopsy, inclusion of patients without steatosis, and exclusion of high risk of biomarkers failures. |
||||||
|
Characteristic of patients |
n |
NashTest AUROC |
Lower 95% |
Upper 95% |
Prevalence Borderline or NASH |
Significance |
|
|
||||||
|
All 257 patients |
257 |
0.78 |
0.72 |
0.84 |
0.38 |
|
|
Stratified according to Group* |
||||||
|
Training Group |
160 |
0.77 |
0.68 |
0.84 |
0.36 |
0.34 |
|
Validation Group |
97 |
0.83 |
0.67 |
0.90 |
0.42 |
|
|
Stratified according to ALT value* |
||||||
|
ALT< 50IU/L |
92 |
0.74 |
0.62 |
0.82 |
0.50 |
0.24 |
|
ALT>= 50 IU/L |
165 |
0.81 |
0.73 |
0.87 |
0.32 |
|
|
Stratified according to Alcohol consumption* |
||||||
|
None |
95 |
0.78 |
0.67 |
0.86 |
0.37 |
0.83 and 0.20 |
|
< 30 g for men and < 20 g for female |
150 |
0.77 |
0.66 |
0.84 |
0.39 |
0.83 and 0.19 |
|
>= 30 g for men or >= 20 g for female |
12 |
1.00 |
0.35 |
1.00 |
0.33 |
0.20 and 0.19 |
|
Stratified according to Quality of biopsy* |
||||||
|
< 25 mm |
194 |
0.78 |
0.71 |
0.84 |
0.39 |
0.98 |
|
>= 25 mm |
63 |
0.78 |
0.63 |
0.88 |
0.37 |
|
|
Fragmented |
148 |
0.77 |
0.68 |
0.84 |
0.36 |
0.46 |
|
Not Fragmented |
109 |
0.81 |
0.71 |
0.88 |
0.40 |
|
|
Patients included or excluded |
||||||
|
Patients without steatosis included** |
272 |
0.79 |
0.72 |
0.84 |
0.39 |
0.83 |
|
High risk of NashTest failures excluded** |
||||||
|
Gilbert excluded |
244 |
0.78 |
0.71 |
0.83 |
0.39 |
0.97 |
|
Acute Inflammation excluded |
254 |
0.78 |
0.72 |
0.84 |
0.38 |
0.98 |
|
|
||||||
|
* Comparison between stratified groups ** Comparison with all 257 patients |
||||||
|
Poynard et al. BMC Gastroenterology 2006 6:34 doi:10.1186/1471-230X-6-34 |
||||||
